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Abstract
Background
In vitro and animal studies have suggested that trazodone, a licensed antidepressant, may
protect against dementia. However, no studies have been conducted to assess the effect of
trazodone on dementia in humans. This electronic health records study assessed the asso-
ciation between trazodone use and the risk of developing dementia in clinical practice.
Methods and findings
The Health Improvement Network (THIN), an archive of anonymised medical and prescrib-
ing records from primary care practices in the United Kingdom, contains records of over 15
million patients. We assessed patients from THIN aged�50 years who received at least two
consecutive prescriptions for an antidepressant between January 2000 and January 2017.
We compared the risk of dementia among patients who were prescribed trazodone to that of
patients with similar baseline characteristics prescribed other antidepressants, using a Cox
regression model with 1:5 propensity score matching. Patients prescribed trazodone who
met the inclusion criteria (n = 4,716; 59.2% female) were older (mean age 70.9 ± 13.1 ver-
sus 65.6 ± 11.4 years) and were more likely than those prescribed other antidepressants (n
= 420,280; 59.7% female) to have cerebrovascular disease and use anxiolytic or antipsy-
chotic drugs. After propensity score matching, 4,596 users of trazadone and 22,980 users
of other antidepressants were analysed. The median time to dementia diagnosis for people
prescribed trazodone was 1.8 years (interquartile range [IQR] = 0.5–5.0 years). Incidence of
dementia among patients taking trazodone was higher than in matched users of other anti-
depressants (1.8 versus 1.1 per 100 person-years), with a hazard ratio (HR) of 1.80 (95%
confidence interval [CI] 1.56–2.09; p < 0.001). However, our results do not suggest a causal
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association. When we restricted the control group to users of mirtazapine only in a sensitivity
analysis, the findings were very similar to the results of the main analysis. The main limita-
tion of our study is the possibility of indication bias, because people in the prodromal stage
of dementia might be preferentially prescribed trazodone. Due to the observational nature of
this study, we cannot rule out residual confounding.
Conclusions
In this study of UK population-based electronic health records, we found no association
between trazodone use and a reduced risk of dementia compared with other antidepres-
sants. These results suggest that the clinical use of trazodone is not associated with a
reduced risk of dementia.
Author summary
Why was this study done?
• Dementia is a growing health concern worldwide with no disease-modifying treatment
available.
• Recent in vitro and animal studies have suggested that trazodone, a licensed antidepres-
sant, might be neuroprotective against dementia.
• No studies have assessed the effects of trazodone on dementia in humans in clinical
settings.
What did the researchers do and find?
• We searched primary care electronic health records from The Health Improvement
Network to identify patients aged�50 years who received at least two consecutive pre-
scriptions for an antidepressant between January 2000 and January 2017 in the UK.
• The risk of dementia among 4,716 users of trazodone was compared to the risk of
420,280 users of other antidepressants with similar baseline characteristics, using a Cox
regression model with 1:5 propensity score matching.
• The incidence of dementia in people prescribed trazodone was higher than in matched
antidepressant users (1.8 versus 1.1 per 100 person-years), with a hazard ratio (HR) of
1.80 (95% confidence interval [CI] 1.56–2.09).
• The median time to dementia diagnosis for users of trazodone was 1.8 years (interquar-
tile range [IQR] = 0.5–5.0 years).
What do these findings mean?
• In this large, UK population-based study, we found no association between trazodone
use and a reduced risk of dementia compared with other antidepressants.
Trazodone use and dementia
PLOS Medicine | https://doi.org/10.1371/journal.pmed.1002728 February 5, 2019 2 / 17
Kong-University College London (HKU-UCL)
Strategic Partnership Fund. RB and KKCM are
funded by the CW Maplethorpe Fellowship. JFH,
DPJO, and RH are supported by the UCLH NIHR
Biomedical Research Center. JFH is also funded by
a Wellcome Trust Clinical Research Career
Development Fellowship. DPJO is also in part
supported by the National Institute for Health
Research (NIHR) Collaboration for Leadership in
Applied Health Research and Care (CLAHRC) North
Thames at Bart’s Health NHS Trust.
Competing interests: I have read the journal’s
policy and the authors of this manuscript have the
following competing interests: ICKW has received
research funding from Bristol-Myers Squibb,
Pfizer, Janssen, the Hong Kong Research Grants
Council, and the Hong Kong Health and Medical
Research Fund outside the submitted work. KKCM
has received personal fees from IQVIA outside the
submitted work. JK is an employee of IQVIA. There
are no other relationships or activities that could
appear to have influenced the submitted work.
Abbreviations: AD, Alzheimer dementia; BNF,
British National Formulary; CI, confidence interval;
eIF2, eukaryotic initiation factor 2; FCS, fully
conditional specification; HR, hazard ratio; IQR,
interquartile range; RCT, randomised controlled
trial; SD, standard deviation; THIN, The Health
Improvement Network; UPR, unfolded protein
response; VD, vascular dementia.
• Trazodone users had an early onset of dementia, which appears to contradict the sugges-
tions from animal studies that trazodone could stop or delay the onset of dementia.
• Whilst the incidence of dementia among patients taking trazodone was higher than that
in patients taking other antidepressants, the risk differences were closer to zero with
increasing duration of treatment, suggesting that people in the prodromal stage of
dementia might be more likely to be prescribed trazodone.
Introduction
Dementia affects more than 47 million people worldwide [1]. Global estimates suggest that the
total economic costs caused by dementia increased from US$279.6 billion in 2000 to $948 bil-
lion in 2016, with an annual growth rate of 15.94%. This included costs of informal care at
$95.1 billion in 2000 and $401.9 billion in 2016, with an annual growth rate of 21.50% [2].
Dementia is characterised by a decline in cognitive functioning which impacts on activities of
daily living [1]. Dementia not only affects patients but also has a significant negative effect on
caregivers. Caregivers of patients with dementia are significantly more stressed than caregivers
for people without dementia, and suffer more serious depressive symptoms and physical prob-
lems [3]. Effective interventions in the prevention and management of dementia are urgently
needed. Alzheimer dementia (AD) and vascular dementia (VD) are the most common forms,
and it can be challenging to differentiate the two clinically [4]. AD is characterised by the pres-
ence of extracellular amyloid plaques and intraneuronal neurofibrillary tangles, which are
accompanied by nerve cell death and tissue loss [5]. The pathophysiological causes of AD are
complex but are thought to involve overactivation of the unfolded protein response (UPR) [6].
Healthy activation of the UPR usually occurs in response to an accumulation of unfolded or
misfolded proteins in the endoplasmic reticulum—e.g., in an attempt to restrict a viral infec-
tion [7].
Dysregulation of the pancreatic endoplasmic reticulum kinase branch of the UPR and its
downstream target, eukaryotic initiation factor 2 (eIF2α), have been identified as potential tar-
gets in the treatment of AD [6], but no safe and effective drugs acting on this pathway exist.
An attempt to identify licensed drugs with anti-eIF2α therapeutic activity that could be repur-
posed for use in AD suggested trazodone 2 hydrochloride, a licensed antidepressant, as a
potential candidate [6]. Subsequent mice studies showed that trazodone was associated with
markedly reduced neuronal loss [6]. Randomised controlled trials (RCTs) of trazodone as a
sleep aid in people with mild to moderate AD showed no evidence of a positive effect on cogni-
tion, and participants experienced potentially detrimental effects on short-term memory [8,
9]. The potential for a predementia neuroprotective effect of trazodone has not been examined
in humans.
Utilising the UK’s primary care electronic health records, we aimed to determine whether
there is an association between trazodone use and the incidence of dementia.
Methods
The study protocol and analysis plan was approved by the Scientific Review Committee for The
Health Improvement Network (THIN) database research (Reference Number: 17THIN048,
June 2017; see S1 Protocol). Further ethics approval was not required for this secondary analysis
of routinely collected data.
Trazodone use and dementia
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Data source and study design
We searched the THIN database, an archive of anonymised medical and prescribing records
of primary care practices in the UK, for electronic primary care health record data for people
with at least two prescriptions for an antidepressant during the study period [10]. Data from
THIN are demographically representative of the UK population [11]. This study used the med-
ical records of patients registered at 744 participating practices, comprising 13,927,536 patients
meeting accepted data quality criteria [12,13] and representing over 6% of the UK population
[11].
Selection of trazodone users and the comparison group
The study population was drawn from the entire population of THIN, with follow-up time
from 1 January 2000 onwards. People were selected for inclusion if they were 50 years of age or
older and received two or more consecutive prescriptions for an antidepressant (Chapter 4.3
of the British National Formulary [BNF]), with the first occurrence being at least 6 months
after the patient’s start of follow-up at their general practice (primary care doctor’s office) to
ensure incident prescribing. This was a dynamic cohort, with follow-up ending at the earliest
of the following: the date the patient left the practice, the date of death, or the date of last data
collection (9 January 2017). Patients were categorised as exposed if they had received two traz-
odone prescriptions but no exposure to any other antidepressant agent prior to trazodone use.
We matched people in the trazodone-treated group to people exposed to any other antidepres-
sant drug currently recommended as monotherapy for depression in British prescribing guide-
lines (comparator group) using a matching algorithm based on propensity scores [14]. Each
trazodone user was matched with up to five users of other antidepressants based on the pro-
pensity score using the greedy matching algorithm [15]. We excluded potential participants
from our analysis if they had any diagnosis of dementia prior to their first prescription for an
antidepressant or a record of cognitive impairment, memory symptoms, or confusion.
Trazodone exposure
Exposure was determined from prescribing records, using drug codes for individual antide-
pressant agents (S1 Table). The index date for each patient was the first prescribing event that
qualified them for study entry (e.g., first exposure to an antidepressant). In the primary analy-
sis, exposure was characterised as “ever exposed” versus “never exposed” to trazodone; trazo-
done-exposed individuals at the start of their follow-up time were classified as ever exposed for
the duration of the study, regardless of any subsequent changes in therapy.
Dementia outcome
The primary outcome was the first recording of a diagnosis of dementia after the index date, as
identified from clinical records using the Read codes in S2 Table. A secondary outcome was
the median time to a diagnosis of dementia. Dementia was defined as any AD, VD, or nonspe-
cific code. Individuals with other identifiable causes for their dementia (Parkinson disease,
Huntingdon disease, Pick disease, alcohol-induced dementia, dementia in other conditions,
HIV, Lewy body disease, Cruetzfeldt-Jacob disease; S2 Table) were censored at the date of the
diagnosis and did not count towards the total number of outcome events.
Propensity score matching
Since the decision to prescribe a drug is likely to be influenced by a patient’s characteristics,
propensity score matching was used to reduce potential bias due to nonrandomised treatment
Trazodone use and dementia
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allocation [14]. Propensity score is a measure of the probability that a patient receives a certain
treatment given their observed characteristics. By matching patients with similar propensity
scores, only patients with similar observed characteristics are compared, and so any observed
difference in the outcome between comparison groups is less likely to be due to the underlying
patient differences. Propensity scores were estimated by logistic regression with the dependent
variable as the treatment of interest (trazodone) and the covariates as follows: observed patient
characteristics (age, sex, general practice identifier); lifestyle variables (smoking status [non-
smoker, current smoker, or ex-smoker], alcohol consumption status [non-drinker, current
drinker, or ex-drinker], and body mass index [underweight, normal weight, overweight, or
obese]); other risk factors for dementia (medical history of depression; anxiety; sleep disorder;
substance abuse; psychotic disorder; attention deficit hyperactivity disorder; personality disor-
der; arrhythmia; heart failure; acute or chronic ischemic heart disease, including myocardial
infarction, hypertension, cerebrovascular disease; diabetes mellitus [recorded any time using
Read codes on or before the index date]); current, past, and non-use of antipsychotic agents,
anti-anxiety medications, and drugs listed under BNF Chapter 2 (cardiovascular system), on
the basis of use on the index date; number of general practice visits in the 12 months before
the index date; and area-level social deprivation (quintile of Townsend score derived from the
2001 census data) [16]. Multiple imputation was used to replace missing smoking status,
drinking status, body mass index, and Townsend score. The fully conditional specification
(FCS) algorithm implemented in SAS’s Proc MI was used to create 25 imputed datasets [17].
The full analysis procedure was applied on each imputed dataset separately, and the results
were combined to obtain an overall estimate. This approach accounts for the variability
between imputed datasets and has been demonstrated as a robust method of applying multiple
imputation techniques in propensity score modelling [18]. All covariates, including the out-
come variable, were included in the imputation model to minimise bias and enhance the preci-
sion of estimates [18,19]. Patients using trazodone and patients using other antidepressants
were matched in a 1:5 ratio by propensity score using a greedy matching algorithm, which has
been demonstrated to perform well in both actual and simulation studies [20]. Standardised
differences were used to assess the differences in patient characteristics and a value of less than
0.1 was considered negligible.
Statistical methods
We measured a hazard ratio (HR) with a 95% confidence interval (CI) for the association
between trazodone use and incident dementia using stratified Cox regression, comparing
patients exposed to trazodone with matched patients exposed to other antidepressants. The
logarithm of HR obtained from each imputed dataset was combined using Rubin’s rules imple-
mented in SAS’s Proc MIANALYZE [18,21]. Sensitivity analyses were conducted using only
complete cases. A two-sided p< 0.05 was considered statistically significant. Stata version 14
(College Station, TX) and SAS version 9.4 (Cary, NC) were used for conducting statistical
analyses.
Additional analyses
To test for the robustness of a study result, we conducted a number of sensitivity analyses.
Firstly, we used a strict definition of AD in which individuals had to have received a Read code
specifying AD and have at least two prescriptions for a cholinesterase inhibitor medication, to
reduce the likelihood of outcome misclassification. Second, we completed an analysis censor-
ing follow-up at the end of trazodone therapy, defined as the end of the last prescription plus
90 days. Third, we conducted an analysis stratified by length of follow-up after starting
Trazodone use and dementia
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trazodone therapy (trazadone use<2 years, 2–3 years, or>3 years) to assess whether any effect
of trazodone varied by duration of treatment. Fourth, we performed additional analyses that
removed any events recorded within 1 month, 6 months, and 12 months after the start of fol-
low-up, because progression to dementia is a gradual process, and diagnosis of dementia soon
after starting an antidepressant treatment is unlikely to be due to the effects of the drug. Lastly,
we conducted an analysis with mirtazapine as the comparison drug in an attempt to further
minimise the between-group differences in prescribing choice. Mirtazapine was chosen
because, like trazodone, it is a sedating antidepressant.
Additionally, we carried out the following five post hoc analyses:
1. We discounted dementia diagnoses within 2 to 10 years of the start of follow-up to further
investigate the risk of dementia with prolonged follow-up.
2. We conducted subgroup analyses including only patients with a diagnosis for depression
and only patients with anxiety at baseline.
3. We re-analysed excluding patients with psychotic disorders (identified by a diagnosis code
for psychosis or a prescription of antipsychotic drugs at baseline). Compared to other anti-
depressants, trazodone is more commonly used off-label for psychotic disorders [22], so
this approach aimed to further reduce the potential systematic differences between compar-
ison groups.
4. We conducted additional analyses to restrict trazodone users to those who were continu-
ously prescribed trazodone at doses of 194 mg or above per day, the dose that was extrapo-
lated from the mice studies [6].
5. We completed subgroup analyses among younger patients who started treatment at 60
years old or younger, because it has been suggested that disease-modifying therapy for
dementia should be administered early in the risk period so that the modification of the
course of the disease is possible [23].
Results
Patient characteristics
There were 465,628 patients in the THIN database had two or more consecutive prescriptions
for an antidepressant and were 50 years of age or older at the time they received their first pre-
scription on or after 1 January 2000. Of these, 4,716 first-line trazodone users met the inclusion
criteria (Fig 1). We were able to match 4,596 patients who were prescribed trazadone to 22,980
users of other antidepressants. The median follow-up time of patients prescribed trazodone
and those prescribed other antidepressants was 3.9 years (interquartile range [IQR] = 1.2–8.8)
and 5.1 years (IQR = 2.1–9.2), respectively. A total of 18,697 out of 424,996 patients (4.4%)
developed dementia during follow-up. The crude incidence rate of dementia per 100 person-
years was more than twice as high in the trazodone group compared with the other antidepres-
sant group (1.8 versus 0.7 per 100 person-years). Crude results showed that trazodone users
were more likely to be diagnosed with dementia earlier (median = 1.7 years; IQR = 0.4–4.7
years) compared with users of other antidepressants (median = 4.3 years; IQR = 1.7–7.8 years).
Smoking status was missing for 8.0% of all individuals who met the inclusion criteria, drinking
status for 16.5%, body mass index for 15.7%, and Townsend score for 30.9%. The characteris-
tics of patients with and without missing data are shown in S3 Table. The distributions of the
observed values and the imputed values data after multiple imputation are presented in S1 Fig
[19,24].
Trazodone use and dementia
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Before propensity score matching, patients prescribed trazodone were older and were more
likely than those prescribed other antidepressants to have cerebrovascular disease and to use
anxiolytic and/or antipsychotic drugs. After propensity score matching, all baseline character-
istics were balanced between treatment groups (Table 1).
Primary analysis
A total of 445 users of trazodone (9.4%) and 18,252 users of other antidepressants (4.3%)
developed dementia during follow-up. After propensity score matching, the absolute number
of dementia cases was 1,997 (434 in the trazodone group and 1,563 in the other antidepressant
group). The incidence of dementia in the trazodone group was higher than the incidence in
the matched comparison cohort (1.8 versus 1.1 per 100 person-years) (Table 2). The HR
showed an association between use of trazodone and the onset of dementia (HR = 1.80; 95%
CI 1.56–2.09; p< 0.001) (Table 3). The median time to a diagnosis of dementia among indi-
viduals using trazodone and those taking other antidepressants was 1.8 years (IQR = 0.5–5.0
years) and 4.1 years (IQR = 1.7–7.7 years), respectively. Complete case analyses yielded similar
results (S4 Table).
Additional analyses
When the primary outcome variable was changed from a generic dementia diagnosis to AD,
no evidence of an association was found (HR = 0.80; 95% CI 0.50–1.29; p = 0.36). When we
censored follow-up at the end of trazodone therapy, our analysis showed a stronger association
between the use of trazodone and the risk of dementia compared with the results of the main
analysis (HR = 2.57; 95% CI 2.11–3.11; p< 0.001). When the follow-up time for the
Fig 1. Flow of patients.
https://doi.org/10.1371/journal.pmed.1002728.g001
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Table 1. Patient characteristics.
Before PS matching After PS matching� Standardised
difference
Trazodone
(N = 4,716)
Other antidepressants
(N = 420,280)
Trazodone
(N = 4,596)
Other antidepressants
(N = 22,980)
Before After
Age, mean ± SD 70.9 ± 13.1 65.6 ± 11.4 70.5 ± 13.0 70.4 ± 12.0 0.43 0.01
Sex (female) 2,794 (59.2) 250,730 (59.7) 2,722 (59.2) 13,603 (59.2) 0.01 <0.001
Cerebrovascular disease 576 (12.2) 33,067 (7.9) 549 (11.9) 2,730 (11.9) 0.15 0.002
Diabetes 480 (10.2) 48,682 (11.6) 471 (10.2) 2,341 (10.2) 0.05 0.002
Arrhythmias 381 (8.1) 28,639 (6.8) 377 (8.2) 1,838 (8.0) 0.05 0.01
Myocardial infarction 926 (19.6) 74,790 (17.8) 910 (19.8) 4,554 (19.8) 0.05 <0.001
Hypertension 1,692 (35.9) 160,276 (38.1) 1,667 (36.3) 8,408 (36.6) 0.05 0.01
Heart failure 256 (5.4) 14,967 (3.6) 249 (5.4) 1,193 (5.2) 0.09 0.01
Personality disorder 50 (1.1) 2,478 (0.6) 47 (1.0) 236 (1.0) 0.05 <0.001
ADHD 2 (0.04) 41 (0.01) 2 (0.04) 5 (0.02) 0.02 0.01
Psychotic disorder 147 (3.1) 4,616 (1.1) 135 (2.9) 627 (2.7) 0.14 0.01
Substance abuse 226 (4.8) 12,304 (2.9) 221 (4.8) 1,071 (4.7) 0.10 0.01
Sleep disorder 133 (2.8) 9,044 (2.2) 127 (2.8) 657 (2.9) 0.04 0.01
Anxiety 856 (18.2) 74,813 (17.8) 843 (18.3) 4,204 (18.3) 0.01 0.001
Depression 1,403 (29.7) 149,007 (35.5) 1,389 (30.2) 6,886 (30.0) 0.12 0.01
Smoking status
Current smoker 1,189 (25.2) 97,539 (23.2) 1,163 (25.3) 5,832 (25.4) 0.06 0.004
Ex-smoker 1,135 (24.1) 111,230 (26.5) 1,112 (24.2) 5,526 (24.0) — —
Non-smoker 2,392 (50.7) 211,511 (50.3) 2,321 (50.5) 11,622 (50.6) — —
BMI, kg/m2
<18.5 203 (4.3) 9,081 (2.2) 186 (4.0) 888 (3.9) 0.18 0.01
18.5–24 1,827 (38.7) 147,816 (35.2) 1,775 (38.6) 8,769 (38.2) — —
25–29 1,757 (37.3) 157,765 (37.5) 1,715 (37.3) 8,688 (37.8) — —
�30 929 (19.7) 105,618 (25.1) 920 (20.0) 4,635 (20.2) — —
Drinking status
Current drinker 3,390 (71.9) 321,515 (76.5) 3,321 (72.3) 16,723 (72.8) 0.11 0.01
Ex-drinker 105 (2.2) 9,708 (2.3) 102 (2.2) 514 (2.2) — —
Non-drinker 1,221 (25.9) 89,057 (21.2) 1,173 (25.5) 5,743 (25.0) — —
Antipsychotic drug use
Current user 429 (9.1) 10,499 (2.5) 369 (8.0) 1,789 (7.8) 0.31 0.02
Past user 114 (2.4) 3,919 (0.9) 103 (2.2) 470 (2.0) — —
Non-user 4,173 (88.5) 405,862 (96.6) 4,124 (89.7) 20,721 (90.2) — —
Cardiovascular drug use
Current user 3,046 (64.6) 253,883 (60.4) 2,965 (64.5) 14,796 (64.4) 0.09 0.005
Past user 203 (4.3) 21,132 (5.0) 198 (4.3) 975 (4.2) — —
Non-user 1,467 (31.1) 145,265 (34.6) 1,433 (31.2) 7,209 (31.4) — —
Anxiolytics drug use
Current user 1,557 (33.0) 97,584 (23.2) 1,501 (32.7) 7,435 (32.4) 0.22 0.01
Past user 538 (11.4) 48,869 (11.6) 516 (11.2) 2,583 (11.2) — —
Non-user 2,621 (55.6) 273,827 (65.2) 2,579 (56.1) 12,962 (56.4) — —
Townsend score
1 (least deprived) 856 (18.2) 106,032 (25.2) 830 (18.1) 4,152 (18.1) 0.22 0.01
2 1,082 (22.9) 98,556 (23.5) 1,049 (22.8) 5,340 (23.2) — —
3 956 (20.3) 89,541 (21.3) 937 (20.4) 4,615 (20.1) — —
4 1,060 (22.5) 76,190 (18.1) 1,035 (22.5) 5,191 (22.6) — —
(Continued)
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Table 1. (Continued)
Before PS matching After PS matching� Standardised
difference
Trazodone
(N = 4,716)
Other antidepressants
(N = 420,280)
Trazodone
(N = 4,596)
Other antidepressants
(N = 22,980)
Before After
5 (most deprived) 762 (16.2) 49,961 (11.9) 745 (16.2) 3,682 (16.0) — —
Number of general practice visits in 12 months
prior to the index date, mean ± SD
27.5 ± 20.4 28.3 ± 20.5 27.4 ± 20.4 27.4 ± 19.8 0.04 <0.001
�The propensity score analysis was performed individually for the 25 imputed datasets. The standardised difference of all covariates was less than 0.1 for all datasets after
PS matching. Patient characteristics in one of the imputed datasets (of which the final result yielded the least standard error in the primary analysis) are presented for
illustration.
Values are expressed as count (percentage) unless otherwise specified. Standardised difference is the absolute difference in means (for continuous variables) or
proportions (for categorical variables) between trazodone users and other antidepressant users divided by the pooled SD.
Abbreviations: ADHD, attention deficit hyperactivity disorder; BMI, body mass index; PS, propensity score; SD, standard deviation.
https://doi.org/10.1371/journal.pmed.1002728.t001
Table 2. Event rates in the primary and secondary analyses.
Crude estimates Adjusted estimates�
Trazodone Other antidepressants Trazodone Other antidepressants
Type of analysis No. of cases/
person-years
Incidence per
100 person-years
No. of cases/
person-years
Incidence per
100 person-years
No. of cases/
person-years
Incidence per
100 person-years
No. of cases/
person-years
Incidence per
100 person-years
Primary analysis 445/25,142 1.8 18,252/
2,516,583
0.7 434/24,793 1.8 1,563/
138,953
1.1
Secondary analyses
AD only 36/25,964 0.1 3,091/
2,550,245
0.1 35/25,576 0.1 254/141,701 0.2
Follow-up time censored
after antidepressant use
293/10,804 2.7 13,394/
1,710,269
0.8 287/10,576 2.7 1,134/97,462 1.2
Trazodone versus
mirtazapine
444/25,122 1.8 821/58,649 1.4 75/3,188 2.4 246/17,139 1.4
Time-updated follow-up
periods
Current 305/11,463 2.7 13,848/
1,763,189
0.8 299/11,225 2.7 1,166/
100,142
1.2
Current <2 years 210/5,788 3.6 4,709/643,224 0.7 205/5,642 3.6 401/35,241 1.1
Current 2–3 years 32/1,356 2.4 1,488/215,879 0.7 32/1,324 2.4 123/12,094 1.0
Current >3 years 63/4,319 1.5 7,651/904,086 0.8 62/4,259 1.5 642/52,807 1.2
Past 140/13,679 1.0 4,404/753,394 0.6 135/13,568 1.0 397/38,810 1.0
Exclusion of recent
dementia
Dementia diagnosis <31
days of follow-up
403/25,137 1.6 17,947/
2,516,474
0.7 393/24,789 1.6 1,525/
138,943
1.1
Dementia diagnosis
<180 days of follow-up
333/25,001 1.3 16,603/
2,509,140
0.7 326/24,658 1.3 1,404/
138,498
1.0
Dementia diagnosis
<365 days of follow-up
278/24,685 1.1 15,243/
2,489,346
0.6 272/24,352 1.1 1,295/
137,377
0.9
�Adjusted estimates were obtained after propensity score matching. Propensity scores were estimated by logistic regression in which the dependent variable was the
treatment of interest and the covariates were the observed patient characteristics, lifestyle variables, and risk factors for dementia listed in Table 1.The propensity score
analysis was performed individually for the 25 imputed datasets. The event rates were similar among the imputed datasets after propensity score matching. The event
rates in one of the imputed datasets (of which the result of the primary analysis yielded the least standard error) are presented for illustration.
Abbreviation: AD, Alzheimer dementia.
https://doi.org/10.1371/journal.pmed.1002728.t002
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trazodone-exposed group was changed to differentiate between groups with current and past
trazodone exposure, a strong association was found for current trazodone exposure (HR =
2.71; 95% CI 2.27–3.23; p< 0.001), but we observed a weaker association with past use
(HR = 1.19; 95% CI 0.84–1.68; p = 0.33). A stratified analysis on length of current trazodone
therapy showed that short exposure to trazodone (<2 years) was more strongly associated
with a higher risk of dementia (Tables 2 and 3).
When we removed any events recorded within 1 month from the start of follow-up
(HR = 1.66; 95% CI 1.42–1.94; p< 0.001), 6 months (HR = 1.50; 95% CI 1.26–1.78; p< 0.001),
and 12 months (HR = 1.36; 95% CI 1.12–1.65; p = 0.002) from the start of follow-up, the results
were closer to null compared with the results of the main analysis. Results of the post hoc anal-
ysis showed that the proportion of patients with dementia in the trazodone group became sim-
ilar to the proportion of patients taking other antidepressants after 3 years (Tables 4 and 5).
In addition, when we restricted the control group to users of mirtazapine only, the findings
were very similar to the results of the main analysis (HR = 1.77; 95% CI 1.38–2.29; p< 0.001).
Similarly, no evidence of a protective association was found in post hoc analyses when analyses
were restricted to patients with depression (HR = 1.46; 95% CI 1.14–1.86; p = 0.003), anxiety
(HR = 1.58; 95% CI 1.28–1.95; p< 0.001), those without psychotic disorders (HR = 1.80; 95%
CI 1.52–2.13; p< 0.001), those who were continuously prescribed trazodone at or above 194
mg per day (HR = 1.27; 95% CI 0.82–1.99; p = 0.28), and those who started treatment at 60
years old or younger (HR = 1.49; 95% CI 0.67–3.29; p = 0.32) (Tables 4 and 5).
Discussion
In this large, population-based study of electronic health records from the UK, we found no
association between trazodone use and a reduced risk of dementia compared with other
Table 3. Results of the primary and secondary analyses (trazodone versus other antidepressants).
Crude estimates Adjusted estimates�
Type of analysis HR (95% CI) p-Value HR (95% CI) p-Value
Primary analysis 2.42 (2.21–2.66) <0.001 1.80 (1.56–2.09) <0.001
Secondary analyses
AD only 1.14 (0.82–1.58) 0.44 0.80 (0.50–1.29) 0.36
Follow-up time censored after antidepressant use 3.51 (3.13–3.94) <0.001 2.57 (2.11–3.11) <0.001
Trazodone versus mirtazapine 1.37 (1.22–1.54) <0.001 1.77 (1.38–2.29) <0.001
Time-updated follow-up periods
Current 3.48 (3.11–3.90) <0.001 2.71 (2.27–3.23) <0.001
Current <2 years 4.88 (4.25–5.60) <0.001 2.98 (2.43–3.65) <0.001
Current 2–3 years 3.43 (2.42–4.87) <0.001 2.32 (1.29–4.17) 0.005
Current >3 years 1.76 (1.38–2.26) <0.001 1.25 (0.78–2.01) 0.35
Past 1.76 (1.48–2.08) <0.001 1.19 (0.84–1.68) 0.33
Exclusion of recent dementia
Dementia diagnosis <31 days of follow-up 2.24 (2.03–2.47) <0.001 1.66 (1.42–1.94) <0.001
Dementia diagnosis <180 days of follow-up 2.01 (1.81–2.24) <0.001 1.50 (1.26–1.78) <0.001
Dementia diagnosis <365 days of follow-up 1.83 (1.63–2.07) <0.001 1.36 (1.12–1.65) 0.002
�Adjusted estimates were obtained after PS matching and by combining the effect estimates of the imputed datasets after PS matching, using Rubin’s rule. PSs were
estimated by logistic regression in which the dependent variable was the treatment of interest and the covariates were the observed patient characteristics, lifestyle
variables, and risk factors for dementia listed in Table 1.
Abbreviations: HR, hazard ratio; AD, Alzheimer dementia; CI, confidence interval; PS, propensity score.
https://doi.org/10.1371/journal.pmed.1002728.t003
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antidepressants. The results were consistent across different patient subgroups, definitions of
dementia outcomes, and treatment durations as well as when comparing specific antidepres-
sants to trazodone. The proportion of patients with dementia observed in both trazodone-
treated individuals and those treated with other antidepressants were consistent with other UK
population-based incidence studies [25].
We found that the incidence of dementia among patients taking trazodone was higher than
that in patients taking other antidepressants. However, our results do not suggest that this
association was causal—the risk differences were closer to zero with increasing duration of
Table 4. Event rates in post hoc analyses.
Crude estimates Adjusted estimates�
Trazodone Other antidepressants Trazodone Other antidepressants
No. of cases/
person-years
Incidence per
100 person-
years
No. of cases/
person-years
Incidence per
100 person-
years
No. of cases/
person-years
Incidence per
100 person-
years
No. of cases/
person-years
Incidence per
100 person-
years
Patients subgroups
Depression 127/9,123 1.4 6,525/907,742 0.7 125/9,015 1.4 447/46,810 1.0
Anxiety 210/13,575 1.5 7,739/
1,094,168
0.7 199/13,214 1.5 774/72,028 1.1
Aged 60 or below 17/10,459 0.2 1,252/
1,206,576
0.1 16/10,360 0.2 66/53,093 0.1
Without psychotic disorders 371/23,175 1.6 17,133/
2,425,546
0.7 370/23,025 1.6 1,263/
127,723
1.0
Trazodone �194 mg per day 42/3,773 1.1 18,252/
2,516,583
0.7 42/3,773 1.1 180/20,055 0.9
Exclusion of dementia that
occurred within 1 to 10
years from index date
��
Excluded dementia <1 year 278/24,685 1.1 15,243/
2,489,346
0.6 272/24,352 1.1 1,295/
137,377
0.9
Excluded dementia <2 years 157/22,625 0.7 11,205/
2,321,935
0.5 154/22,380 0.7 951/128,689 0.7
Excluded dementia <3 years 129/21,538 0.6 9,538/
2,195,780
0.4 127/21,309 0.6 800/122,234 0.7
Excluded dementia <4 years 109/20,160 0.5 8,009/
2,046,245
0.4 108/19,976 0.5 663/114,476 0.6
Excluded dementia <5 years 86/18,785 0.5 6,641/
1,880,165
0.4 85/18,612 0.5 547/105,934 0.5
Excluded dementia <6 years 70/17,126 0.4 5,439/
1,704,840
0.3 70/16,991 0.4 452/96,633 0.5
Excluded dementia <7 years 60/15,841 0.4 4,355/
1,524,010
0.3 60/15,721 0.4 358/86,951 0.4
Excluded dementia <8 years 47/14,139 0.3 3,377/
1,339,852
0.3 47/14,044 0.3 265/77,129 0.3
Excluded dementia <9 years 37/12,272 0.3 2,555/
1,153,269
0.2 37/12,224 0.3 203/67,149 0.3
Excluded dementia <10 years 23/10,337 0.2 1,824/971,014 0.2 23/10,300 0.2 156/56,397 0.3
�Adjusted estimates were obtained after propensity score matching. Propensity scores were estimated by logistic regression in which the dependent variable was the
treatment of interest and the covariates were the observed patient characteristics, lifestyle variables, and risk factors for dementia listed in Table 1. The propensity score
analysis was performed individually for all the 25 imputed datasets. The event rates were similar among the imputed datasets after propensity score matching. The event
rates in one of the imputed datasets (of which the result of the primary analysis yielded the least standard error) are presented for illustration.
��Exclusion of dementia that occurred within 1 to 10 years from index date for all patients (no subgroup analysis).
https://doi.org/10.1371/journal.pmed.1002728.t004
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treatment, suggesting the possibility of reverse causality, in which people in the prodromal
stage of dementia might be more likely to be prescribed trazodone. This is consistent with our
observation that the median time to diagnosis of dementia among trazodone users was much
shorter than that among other antidepressants users (1.8 versus 4.1 years), despite controlling
for all observable prodromal characteristics using propensity scores. However, when we
excluded dementia diagnoses recorded during the early years of starting treatment, the results
suggested that there was no association between trazodone use and dementia diagnosed after 3
or more years after starting treatment. In particular, trazodone may be prescribed to individu-
als with sleep problems, which may be an independent risk factor for AD as well as an early
sign of dementia [26,27]. However, the findings remained consistent when making a compari-
son with another sedating antidepressant (mirtazapine). Our study findings are consistent
with those of the only RCT that has examined cognitive outcomes in patients with mild to
moderate AD taking trazodone, which reported that trazodone had no positive effect on cogni-
tion when compared to placebo [28]. Another RCT of trazodone as a sleep aid in patients with
insomnia reported small impairments in short-term memory in trazodone users [8]. Hence,
neither the findings of this study nor the existing evidence supports the idea that trazodone
could have a neuroprotective effect in dementia.
Because depressive symptoms can be part of the clinical presentation of unrecognised
dementia, people taking an antidepressant may represent an apparently at-risk population that
may go on to develop dementia [1]. The early occurrence of dementia in individuals taking
trazodone shown in this study appears to contradict the idea that trazodone might stop or
delay dementia onset, which had been based on indications that trazodone is neuroprotective
in prion-diseased mice and tauopathy-frontotemporal dementia mice, considered to offer a
Table 5. Results of post hoc analyses (trazodone versus other antidepressants).
Crude estimates Adjusted estimates�
HR (95% CI) p-Value HR (95% CI) p-Value
Patients subgroups
Depression 1.93 (1.62–2.30) <0.001 1.46 (1.14–1.86) 0.003
Anxiety 2.18 (1.90–2.50) <0.001 1.58 (1.28–1.95) <0.001
Started treatment at aged 60 or below 1.51 (0.93–2.43) 0.09 1.49 (0.67–3.29) 0.32
Without psychotic disorders 2.25 (2.03–2.49) <0.001 1.80 (1.52–2.13) <0.001
Trazodone �194 mg per day 1.52 (1.12–2.06) 0.007 1.27 (0.82–1.99) 0.28
Exclusion of dementia that occurred within 1 to 10 years from index date
Excluded dementia <1 year 1.83 (1.63–2.07) <0.001 1.36 (1.12–1.65) 0.002
Excluded dementia <2 years 1.60 (1.40–1.84) <0.001 1.17 (0.94–1.46) 0.16
Excluded dementia <3 years 1.40 (1.20–1.64) <0.001 0.99 (0.76–1.29) 0.95
Excluded dementia <4 years 1.34 (1.12–1.59) 0.001 0.95 (0.71–1.26) 0.70
Excluded dementia <5 years 1.33 (1.10–1.61) 0.003 0.95 (0.67–1.36) 0.78
Excluded dementia <6 years 1.25 (1.01–1.55) 0.04 0.87 (0.58–1.31) 0.50
Excluded dementia <7 years 1.23 (0.97–1.55) 0.09 0.85 (0.54–1.36) 0.50
Excluded dementia <8 years 1.30 (1.01–1.67) 0.04 0.94 (0.56–1.58) 0.81
Excluded dementia <9 years 1.30 (0.98–1.74) 0.07 0.98 (0.51–1.89) 0.96
Excluded dementia <10 years 1.35 (0.97–1.86) 0.07 1.00 (0.46–2.20) 0.99
�Adjusted estimates were obtained after propensity score matching and by combining the effect estimates of the imputed datasets after propensity score matching, using
Rubin’s rule. Propensity scores were estimated by logistic regression in which the dependent variable was the treatment of interest and the covariates were the observed
patient characteristics, lifestyle variables, and risk factors for dementia listed in Table 1.
Abbreviations: HR, hazard ratio; CI, confidence interval.
https://doi.org/10.1371/journal.pmed.1002728.t005
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plausible neurobiological model for early symptomatic dementia in humans [6]. The reason
why trazodone is neuroprotective in animal models but has been ineffective in humans is
unknown. However, it is not uncommon that drugs that have tested safe and effective in ani-
mal models do not translate into clinical efficacy in humans [29]. Indeed, so far, none of the
drugs that slowed neurodegeneration in animal models have been successful in humans [30].
Preclinical findings that do not translate into clinical settings are particularly common in
neurodegenerative disease research due to the complex mechanisms involved that are difficult
to mimic in animal models [29,31]. Although animal models can replicate some aspects of the
disease at a time, the progression of dementia in humans involves a spectrum of neuropatho-
logic changes [31], which could affect the translatability of findings from animal studies to
human clinical settings. A noteworthy exception is trials investigating the beneficial effects of
lithium, which may improve cognitive performance in people with dementia. It is difficult to
investigate the neuroprotective effects of any drug being considered for repurposing in the
treatment of AD in clinical trials because of the narrow therapeutic window for CNS effects,
the need to maintain physician masking to trial treatment allocation, and the long treatment
period needed to assess any effect on cognitive decline. Therefore, the results of observational
studies using routinely collected data are relevant. To our knowledge, this is the first clinical
population-based study that has examined the risk of dementia with trazodone use. We utilised
the THIN database, in which the data are representative of the UK population and reflect
actual clinical practice. Data from THIN have also been used in the context of dementia in UK
primary care settings to inform care [32–34].
There are some limitations to our study. All of the patients in our study received antidepres-
sant agents. We chose not to have a nonexposed control group because we would not have been
able to control for important confounders. For example, we would not be able to measure the
effects of the neuropsychiatric scrutiny given to patients prescribed antidepressants. Dementia
diagnoses are more likely to be made and at an earlier stage in patients who are already seeing
and receiving treatment from physicians for depression or other neuropsychiatric disorders.
Whilst this may have increased the likelihood of enhanced case detection in our study popula-
tion, we believe that it is unlikely to have affected users of trazodone differently from those using
other antidepressants. Nondifferential misclassification of undiagnosed or wrongfully diagnosed
patients may have affected our results. We were also unable to assess whether the clinical diagno-
ses of AD met the pathological criteria for AD at autopsy. However, any bias resulting from non-
differential misclassification would be directed towards the null and is unlikely to have affected
the interpretation of our results. We did not control for the adjuvant use of other antidepressants
in trazodone users. So far, no other antidepressants have been suggested to affect the likelihood
of developing dementia in its own right or when used concurrently with trazodone. Further-
more, given that we assessed patients taking other antidepressants as the comparator group, this
would tend to have biased the results towards null and so is unlikely to affect our conclusion.
Although patients were well matched on many baseline characteristics using propensity
scores, it is possible that the observed comorbidities were insufficient to identify and account
for patients experiencing early symptoms of dementia. However, the early occurrence of
dementia among individuals prescribed trazodone suggested a lack of association between
trazodone use and delayed onset of dementia. Data in the THIN database are not collected for
research purposes, and lifestyle factors such as exercise and diet are not recorded. However,
these factors are not anticipated to be involved in the decision to prescribe trazodone and
other antidepressants and therefore would be unlikely to introduce confounding by indication.
To reduce residual confounding, we included patients who were likely to have similar indica-
tions for starting an antidepressant in the comparator group. We conducted several sensitivity
analyses, and the results were found to be robust. In light of the recent literature on
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anticholinergic drug burden and risk for dementia, we also conducted a post hoc analysis in
which we found an evenly distributed baseline exposure to anticholinergic agents (standard-
ized differences <0.1). Furthermore, the results of a complete-case analysis controlled for the
use of anticholinergic drugs in the propensity score model were consistent with the results of
our original analyses. While dementia events were identified using Read codes and prescrip-
tions, it was not possible to measure the severity of dementia at diagnosis [32]. We were also
unable to obtain measurements of biomarkers for neurodegeneration among trazodone users.
Reliable continuous measures of cognitive performance to assess the extent of neurodegen-
eration over time are not available within the THIN dataset. However, receiving a new diagno-
sis for dementia is itself a clinical marker that reflects the progression of neurodegeneration.
The lack of continuous measurements of cognitive function over time would only have been a
problem if we had been assessing whether trazodone could slow the progression of dementia
compared with other antidepressants. Because it is possible to reliably identify a diagnosis of
dementia in a large clinical database such as THIN, these datasets offer an opportunity to con-
duct large-scale, contemporary studies with results that are generalisable to clinical practice.
Conclusion
Using electronic health records from UK primary care, we showed that trazodone use was not
associated with a reduced risk of dementia compared with other antidepressants. These results
refute the suggestions from animal studies that trazodone might stop or delay the onset of
dementia in patients at the prodromal stage of dementia.
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